Bionomics Investor Presentation Deck

Phase 1 1 1 1b 1b 1b 1 1 1 2a 2a 2 Summary of BNC210 Clinical Trials: Excellent Safety and Tolerability Profile in Healthy Subjects and Patients 2b Description Single Ascending Dose Safety and PK Single Ascending Dose Safety and PK; Food Effect Single Ascending Dose Safety and PK; Food Effect Lorazepam Comparison CCK-4 Panic Attack Model Multiple Ascending Dose Safety and PK; Expanded Cohort for EEG Target Engagement Suspension and Tablet Formulation PK Comparison Single Ascending Dose Safety and PK Multiple Dosing Safety and PK Imaging and Behavioral Study In Generalized Anxiety Disorder Agitation in the Elderly in Hospital Setting Bionomics Post-Traumatic Stress Disorder Post-Traumatic Stress Disorder Participants / Setting Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic EEG Electroencephalography PK Pharmacokinetic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Healthy volunteers / In-clinic Generalized anxiety disorder patients / In-clinic Agitated elderly patients / Hospital Post-traumatic stress disorder patients / Out-patient Post-traumatic stress disorder patients / Out-patient * The number of enrolled subjects who were administered BNC210; other enrolled subjects were administered placebo only CCK-4 = Cholecystokinin Tetrapeptide Subjects Enrolled / Administered BNC210* 32/24 4/3 47/40 24/22 60/59 56/44 6/6 5/5 10/10 27/25 38/18 193/143 Ongoing BNC210 Formulation and Doses Suspension; single doses (5 to 2000 mg) Suspension; single doses (300 to 2000 mg) Capsule; single doses (300 to 3000 mg) Suspension; single doses (300 and 2000 mg) Suspension; single doses (2000 mg) Suspension; multiple doses (150 to 1000 mg twice daily for 8 days) Suspension and tablet; single doses (300 mg) Tablet; single doses (600 to 1200 mg) Tablet; multiple doses (900 mg twice daily for 7 days) Suspension; single doses (300 and 2000 mg) Suspension; multiple doses (300 mg twice daily for 5 days) Suspension; multiple doses (150, 300 or 600 mg twice daily for 12 weeks) Tablet; multiple doses (900 mg twice daily for 12 weeks) Location Australia Australia US 30 France France France Australia Australia Australia UK Australia Australia US US

View entire presentation